These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28901082)

  • 21. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension.
    Foulds G; Luke DR; Teng R; Willavize SA; Friedman H; Curatolo WJ
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():37-44. PubMed ID: 8818844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relative bioavailability and bioequivalence of azithromycin tablets in healthy volunteers].
    Yang L; Zheng H; Tu N
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1260-1, 1263. PubMed ID: 17715042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system.
    Si EC; Cheung PS; Bowman L; Hosseini K
    Curr Eye Res; 2009 Jun; 34(6):485-91. PubMed ID: 19899983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field. Pediatric Study Group of Azithromycin].
    Fujii R; Abe T; Tajima T; Terashima I; Meguro H; Sunakawa K; Yokota T; Akita H; Iwata S; Takeuchi Y
    Jpn J Antibiot; 1995 Sep; 48(9):1074-92. PubMed ID: 7474330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence study of two azithromycin formulations in healthy subjects.
    Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Harinanto G; Santoso ID; Sari AP; Rimainar A
    Arzneimittelforschung; 2009; 59(9):471-5. PubMed ID: 19856795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method.
    Tian JC; Zhang XL; Cui JR; Li XG
    Curr Med Sci; 2022 Aug; 42(4):863-870. PubMed ID: 35678908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field. Pediatric Study Group of Azithromycin].
    Tajima T; Kobayashi M; Terashima I; Meguro H; Sunakawa K; Yokota T; Akita H; Iwata S; Takeuchi Y; Fujii R
    Jpn J Antibiot; 1995 Sep; 48(9):1051-73. PubMed ID: 7474329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetic and clinical evaluation of azithromycin in the pediatric field].
    Kitamura K; Kamiya H; Nakano T; Sakurai M
    Jpn J Antibiot; 1997 Feb; 50(2):206-14. PubMed ID: 9100081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
    Stewart WC; Crean CS; Zink RC; Brubaker K; Haque RM; Hwang DG
    Am J Ophthalmol; 2010 Nov; 150(5):744-751.e2. PubMed ID: 20813346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.
    Sutton AL; Acosta EP; Larson KB; Kerstner-Wood CD; Tita AT; Biggio JR
    Am J Obstet Gynecol; 2015 Jun; 212(6):812.e1-6. PubMed ID: 25595580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.
    Wilms EB; Touw DJ; Heijerman HG
    J Cyst Fibros; 2008 Jan; 7(1):79-84. PubMed ID: 17599845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study on azithromycin in 10% fine granules and 100mg capsules in the field of pediatrics].
    Motohiro T; Nagai K; Yamada S; Tsumura N; Yamada T; Oda K; Sakata Y; Kato H; Gakuen Y; Imai S; Sasaki H; Morita J; Ikezawa S; Matsuo Y; Yamashita Y; Aramaki M; Araki H; Yasuoka C; Hayashi M; Ono E; Hashimoto N; Kubota K; Kawakami A; Toyoda A; Wada M
    Jpn J Antibiot; 1997 Mar; 50(3):272-97. PubMed ID: 9634360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field].
    Akita H; Sato Y; Kusumoto Y; Iwata S; Takeuchi Y; Aoyama T; Yokota T; Sunakawa K
    Jpn J Antibiot; 1996 Oct; 49(10):899-916. PubMed ID: 8986553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.
    Akpek EK; Vittitow J; Verhoeven RS; Brubaker K; Amar T; Powell KD; Boyer JL; Crean C
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):433-9. PubMed ID: 19857105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats.
    Wan YF; Huang ZH; Jing K; Li J; Wang Y; Xu CQ; Chen JH; Zheng YL
    Respir Care; 2015 Jan; 60(1):128-34. PubMed ID: 25249648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial.
    Savaris RF; Teixeira LM; Torres TG; Edelweiss MI; Moncada J; Schachter J
    Obstet Gynecol; 2007 Jul; 110(1):53-60. PubMed ID: 17601896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of azithromycinin rabbit lacrimal glands and conjunctiv a.
    Karcioglu ZA; Ahmed WS; Raines D; El-Yazigi A
    Ophthalmic Res; 1999; 31(1):47-52. PubMed ID: 9831822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin.
    Kuehne JJ; Yu AL; Holland GN; Ramaswamy A; Taban R; Mondino BJ; Yu F; Rayner SA; Giese MJ
    Am J Ophthalmol; 2004 Oct; 138(4):547-53. PubMed ID: 15488779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.